7th ed London, United Kingdom: Elsevier Churchill Livingstone; 2012: 792.
By December 2017, the FDA reported 40,882 adverse event reports had been filed over Abilify.Pathological gambling secondary to dopaminergic therapy in Parkinson's disease.Cloninger CR, Svrakic DM, Przybeck.2007; 6: 384 386.When they fail that duty, they may be liable by law for injuries their products cause.2003; 61: 422 423.Abilify is considered to be an anti-psychotic.They are more likely to develop conditions such as sleep deprivation, hypertension, peptic ulcers, and cardio-vascular problems that are commonly brought on in part by excess stress.Gambling is of special concern because it can have a serious financial impact on a person, and put a strain on their entire family.Prevalence of problem and pathological gambling in Parkinson's disease.Medical hazards of the internet: gambling in Parkinson's disease.2005; 162: 507 512.
Breen RB, Zuckerman.
2006; 144: 241 244.Rexulti is also manufactured by Otsuka America Pharmaceutical Inc.Abilify became one of the top-selling drugs in the.S.McNamara P, Durso R, Harris.Abilify and Rexulti work by rebalancing dopamine and serotonin receptors to improve thinking, mood and behavior.Potenza MN, Maciejewski PK, Mazure.Any substance that encourages a behavior such as impulsive gambling is far too costly.
Most pharmaceutical lawsuits center around a companys failure to properly warn patients of potential dangers, and with Abilify it seems that many doctors were not given the information they needed in order to properly inform their patients of the risks involved in taking the medication.
Soc Work Public Health.
Patients who suffered impulse control issues and pathological gambling compulsions allege that they could have avoided the financial losses and problems related to their addiction if the drug maker would have provided warnings about the side-effects.
Abilifys own information page lists many potential side effects including increased risk of stroke, increased blood sugar, weight gain and more.